New form of existing wake-promoting drug approved

Alkaptonuria affects approximately 1 in 250,000 to 1 million people in the United States.

Marta Wosinska, PhD, and Joey Mattingly, PharmD, MBA, PhD, joined Drug Topics to help us understand how pharmaceutical tariffs could potentially impact the pharmacy industry.

The decision makes the therapy the first and only twice-yearly option available in the United States for PrEP.

In this episode, Natalie DiPietro Mager, PharmD, PhD speaks with David Bright, PharmD, MBA, professor at Ferris State University College of Pharmacy.

Researchers explored the incidence of pneumococcal hemolytic uremic syndrome in children living in Sweden from January 2009 to December 2024.

The review explored the “emerging” term gut-skin axis and aimed to decipher the bidirectional signaling of the skin and gastrointestinal tract during homeostatic and disease states.